Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ruxolitinib phosphate by Novartis for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Ruxolitinib phosphate is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...
Ruxolitinib phosphate by Incyte for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome: Likelihood of Approval
Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine...
Ruxolitinib phosphate by Novartis for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Ruxolitinib phosphate is under clinical development by Novartis and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...